Introduction {#S0001}
============

Over the last few years, with the emergence of anti-tumor necrosis factor (anti-TNF) agents, treatment options have significantly increased for patients with chronic inflammatory rheumatism (CIR), including rheumatoid arthritis (RA), and ankylosing spondyloarthritis (AS). However, patient adherence to these treatments appears to be sub-optimal. In the Smolen study, the percentage of patients that demonstrated good adherence with an anti-TNF agent was 75% for those with RA, 68% for those with AS, and 70% for those with psoriatic arthritis (PsA).[@CIT0001] Poor patient adherence to treatments has proven to be a major roadblock to effective management.[@CIT0002] Treatment adherence is determined by the complex interactions of several factors: the disease, drug therapies, demographic and socioeconomic factors, treatment beliefs, the opinions of patients and their friends or family, and the other healthcare system services (advice, education, etc.).[@CIT0001],[@CIT0003],[@CIT0004]

Therapeutic patient education (TPE) is now recognized as a crucial tool in managing conditions like CIR.[@CIT0005],[@CIT0006] Among the factors likely to improve treatment adherence, TPE has been the most extensively studied, and this approach is supported by the highest level of evidence.[@CIT0007]--[@CIT0012] Consequently, we implemented a TPE program in our department, with the aim of encouraging patients to self-manage subcutaneous biotherapies. France's national authority of health (Haute Autorité de Santé, HAS) recommended structuring TPE in four stages (educational diagnosis, educational objectives, education, and assessment) in individual consultations or group sessions.[@CIT0013] In the current nursing practice, this structure was complicated by organizational issues, and sometimes, only a brief individual informative consultation with a nurse could be delivered, without a previous educational diagnosis. A previous observational study, conducted by nurses,[@CIT0014] was designed to assess which educational model was the most effective for ensuring that patients with CIR could manage their subcutaneous anti-TNF treatments in the safest way possible. That study demonstrated that combining individual TPE consultations with group sessions resulted in higher knowledge and competence scores, compared to providing individual TPE alone or simply providing information to patients that required anti-TNF treatment.[@CIT0014]

The primary endpoint of the present, ancillary study was to assess adherence to subcutaneous anti-TNF in patients with CIR (RA, AS, and PsA) that received TPE in different forms. We also aimed to study how knowledge about anti-TNF influenced adherence.

Patients/Methods {#S0002}
================

Study Design {#S0002-S2001}
------------

This retrospective, observational, monocentric study of current care practices included all patients treated with subcutaneous anti-TNF that had received at least one TPE session, delivered by a nurse, between 2009 and 2013. The TPE sessions were categorized a posteriori, according to the following TPE models:[@CIT0015],[@CIT0016]

Model 1 (M1): A brief individual consultation lasting approximately half an hour was provided that was informative in nature; ie, the pedagogical "behavioral model", which is focused on information. The consultation was with a nurse, and it was not preceded by an educational diagnosis.

Model 2 (M2): At least two individual consultations were provided lasting approximately 1 hour, which included the following the four recommended stages: (1) educational diagnosis, (2) objectives, (3) education, and (4) assessment. This "constructive model" was a singular development model, based on the patient's potential, resources, and relationship with his/her physician. An educational diagnosis was performed to develop an understanding of the patient, with the following questions: Who is the patient? What does he/she do, what does he/she know, and what does he/she believe? How does he/she live? What are his/her future plans? This diagnosis included a meeting between the nurse and patient to negotiate and prioritize goals; then a later meeting to assess those goals.

Model 3 (M3): Individual and group sessions that included all four stages; ie, the "social-constructivist model". This social development model was based on group interactions and potential. All four recommended stages were provided via individual and group sessions. The two individual sessions for diagnosis and for evaluation lasted approximately 1 hour each. The group sessions lasted approximately 1 hour and included six to eight patients per group.

For all three educational models, the treatment benefits and risks were presented to each patient. In addition, patients learned risk prevention methods (eg, vaccinations, dental hygiene, etc.); safe injection conditions versus those considered unsafe (eg, infection symptoms or fever, wound, dentistry, surgery, pregnancy); and the proper subcutaneous injection technique.

Data Collection {#S0002-S2002}
---------------

Anti-TNF treatment adherence was assessed with the Morisky Medication Adherence Scale (MMAS-4™), which included four questions, or with a generic scale for evaluating treatment adherence behavior.[@CIT0017]--[@CIT0019] The questions were (1) Do you ever forget to take your treatment? (2) Do you sometimes have difficulty remembering to take your treatment? (3) When you feel well, do you sometimes stop taking your treatment? (4) If you ever feel worse after taking your treatment, do you sometimes stop? The MMAS-4 was previously validated as a useful, reliable tool for treatment adherence. It was shown to have high sensitivity (0.81) and moderate specificity (0.44).[@CIT0017]--[@CIT0019] Adherence was classed as follows: good (MMAS-4 = 4), moderate (MMAS-4 = 2--3), and poor (MMAS-4 = 0--1).

Each patient's knowledge about anti-TNF treatment was assessed with the Biosecure self-completed questionnaire, which was developed and validated by the TPE section of the French Society for Rheumatology (Société française de Rhumatologie, SFR).[@CIT0020] This questionnaire featured 55 items (scored 0 to 100), which covered various capacity levels, such as managing infections, vaccinations, and everyday situations (eg, travel, surgery, or planned pregnancy). It also included 30 questions for evaluating knowledge (theoretical knowledge) and 25 questions that described seven hypothetical situations (practical knowledge). The patient selected one of three possible responses: yes/no/I do not know.

The Biosecure score was divided into different skill areas, including general knowledge, reaction when faced with infection or fever, reaction when faced with a wound, prevention of infection, vaccinations, dental hygiene, planned surgery, planned pregnancy, communication, and subcutaneous treatment. One of the questions and one hypothetical clinical setting specifically addressed subcutaneous biotherapies; thus, those items did not apply to patients that received intravenous biotherapies. Consequently, we assessed competence in two parts, one part included all patients that received either intravenous or subcutaneous biotherapy; and the second part only included patients that received subcutaneous biotherapy. Each correct answer received one point. The knowledge score was calculated as the total of all points received, out of 100. The higher the score, the better the knowledge.

The following social-demographic data were collected: date of birth, gender, marital status, socio-professional class, education, and the distance travelled to reach the clinics. The following clinical data were also collected: CIR diagnosis and year of diagnosis; the treatment year (the year the biotherapy was initiated and stopped); the number of consultations; the date of the last consultation; the type of management (in-hospital only or mixed); and the frequency of injections.

Study ethics approval was obtained on 30 June 2017 (CECIC Rhône-Alpes-Auvergne, Grenoble, IRB 5921), all patients provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.

Statistical Considerations {#S0002-S2003}
--------------------------

All analyses were performed with Stata software (Version 13, StataCorp, College Station, TX). All analyses used a two-sided Type I error of α=5%. Patient characteristics are expressed as the mean ± standard-deviation (SD) or the median and interquartile range (IQR) for continuous data. The assumption of normality was assessed with the Shapiro--Wilk test. Categorical parameters are expressed as numbers and percentages. Quantitative variables were compared between independent groups with an ANOVA or a Kruskal--Wallis test, when ANOVA conditions were not met (normality and homoscedasticity, evaluated with the Bartlett test). When appropriate, post hoc tests were performed to account for multiple comparisons (Tukey--Kramer for the ANOVA and Dunn for the Kruskal--Wallis test). Comparisons between independent groups were performed with the Chi-square or Fisher's exact test for categorical variables. When appropriate, a post hoc test was used (Marascuillo procedure).

To determine factors associated with observations that were considered a Class 3 variant, a multivariate polynomial ordinal regression model was performed with the stepwise approach (backward and forward). The covariates were fixed according to univariate results (p \<0.05) and clinical relevance. Particular attention was paid to the study of multicollinearity and interactions between covariates: 1) we studied the relationships between the covariates and 2) we evaluated the impact of adding or deleting variables on the multivariate model. Results are expressed as relative risk ratios (RR) and 95% confidence intervals (95% CI).

Results {#S0003}
=======

This study included 193 patients. The cohort included 124 women and the mean population age was 53.3 ± 14.8 years. The mean CIR duration was 10 years \[5; 18\]. Patients were diagnosed with RA (n = 113), AS (n = 73), and PsA (n = 7). Among the 193 patients, injections were administered once per week (n = 108; 60%), once every 15 days (n =68; 35%), or once per month (n = 17; 5%). We found good compliance in 146 (75.7%), moderate compliance in 34 (17.6%), and poor compliance in 13 (6.7%) patients.

The M1, M2, and M3 models were followed by 92, 80, and 21 patients, respectively. Characteristics of patients according to their educational model were presented in [Table 1](#T0001){ref-type="table"}. Patients attended on median 1 \[1;1\] session in group M1, 2 \[1;3\] in group M2 and 4 \[4;5\] sessions in group M3. The median number of TPE session attended by patients was 2 \[1;3\] and was no different according to medication adherence (p=0.46).Table 1Characteristics of Patients According to Their Educational ModelModel 1 N = 92Model 2 N = 80Model 3 N = 21p-valueGender Female, n (%)55 (59.8)51 (63.8)18 (85.7)0.08Age, mean ± SD54.1 ± 15.651.5 ± 14.157.0 ± 13.40.24Education, n (%) Elementary school10 (11.2)3 (3.7)3 (15.0)0.15 Middle school18 (20.2)19 (23.8)5 (25.0) High school34 (38.2)39 (48.7)4 (20.0) University27 (30.4)19 (23.8)8 (40.0)Socio-professional status, n (%) Employed41 (45.0)46 (59.7)9 (42.9)0.16 Retired31 (34.1)22 (28.6)10 (47.6) Unemployed19 (20.9)9 (11.7)2 (9.5)Marital status, n (%) Married/Civil union55 (64.0)53 (71.6)16 (84.2)0.14 Single21 (24.4)19 (25.7)3 (15.8) Widowed10 (11.6)2 (2.7)0 (0.0)Type of care In-hospital, n (%) (vs mixed)40 (44.4)35 (44.3)9 (45.0)0.99Pathologies, n (%) RA55 (59.8)41 (51.3)17 (81.0)0.09 AS34 (37.0)36 (45.0)3 (14.3) Other3 (3.3)3 (3.7)1 (4.7)Disease duration \[IQR\]11 \[5--21\]10 \[4.5--17.5\]5 \[4--7\]0.01\*Time before treatment initiation \[IQR\]4 \[2--8\]3 \[1--5\]2 \[1--4\]0.003\*Injection frequency, n (%) 1/week (Etanercept)46 (50.0)48 (60.0)14 (66.7)0.03\* 1/15 days (Adalimumab, Certolizumab)42 (45.7)22 (27.5)4 (19.0) 1/month (Golimumab)4 (4.3)10 (12.5)3 (14.3)[^1]

The M3 group (TPE given in group and individual consultations) displayed significantly worse anti-TNF adherence compared to the other two groups (p=0.04) ([Figure 1](#F0001){ref-type="fig"}). The proportions of patients that showed good anti-TNF adherence were significantly different between M1 and M3 (p=0.049) and between M2 and M3 (p=0.04); in contrast, no difference was found between M1 and M2 (p=0.70; [Figure 1](#F0001){ref-type="fig"}).Figure 1Morisky Medication Adherence Scale (MMAS-4) scoring for the three therapeutic patient education models (models 1--3). MMAS-4 scores are color-coded; adherence was categorized as follows: MMAS=1: poor; MMAS=2 or 3: moderate; MMAS=4: good.**Notes:** Adapted with permission from Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care*. 1986;24:67--74.[@CIT0017] Use of the MMAS is protected by US and International copyright and Trademark laws. Permission for use is required. A license agreement is available from Donald E. Morisky, MMAS Research (MORISKY), 294 Lindura Court, Las Vegas, NV 89138-4632 dmorisky\@gmail.com.

[Table 2](#T0002){ref-type="table"} presents the study of relationships between medical adherence and potential influencing factors, categorized by patient characteristics. In univariate analysis, only age of patients was associated with good adherence, ie, older patients showed better adherence than younger patients: 50.5±16.7 for poor adherence, 45.9±15.2 for moderate adherence and 55.3±14.0 for good adherence (p=0.005). These findings, including association between medical adherence and TPE models, were confirmed by multivariable analysis, adjusted for age, gender, and the time interval before commencing treatment. For age, relative risk (RR) was 0.95 \[0.91; 0.99\] (p=0.042) between poor and good adherence. For TPE models, the M3 group (TPE given in group and individual consultations) displayed significantly worse anti-TNF adherence (between poor and good adherence) compared to the other two groups (vs M1: RR=9.10 \[1.79; 46.3\] (p=0.008); vs M2: RR=11.0 \[2.06; 58.9\] (p=0.005)). In multivariable analysis, no relation with medical adherence was highlighted for gender RR=0.42 \[0.08; 2.08\] (p=0.286) and for time before treatment initiation RR=1.18 \[0.96, 1.45\] (p=0.119).Table 2Anti-TNF Adherence According to Patient CharacteristicsPoor Adherence N = 13Moderate Adherence N = 34Good Adherence N = 146p-valueGender, n (%) Female11 (8.9)18 (14.5)95 (76.6)0.12 Male2 (2.9)16 (23.2)51 (73.9) Age, mean ± SD50.5 ± 16.745.9 ± 15.255.3 ± 14.00.005\*Education, n (%) Elementary school1 (6.3)1 (6.3)14 (87.4)0.11 Middle school3 (7.1)4 (9.5)35 (83.4) High school2 (2.6)15 (19.5)30 (77.9) University7 (13.0)12 (22.2)35 (64.8)Socio-professional status, n (%) Employed8 (8.3)19 (19.8)69 (71.9)0.33 Retired4 (6.4)7 (11.1)52 (82.5) Unemployed1 (3.3)8 (26.7)21 (70.0)Marital status, n (%) Married/Civil union9 (7.3)19 (15.3)96 (77.4)0.23 Single0 (0.0)10 (23.3)33 (76.7) Widowed1 (8.3)1 (8.3)10 (83.4)Type of care, n (%) Mixed8 (7.6)21 (20.0)76 (72.4)0.32 In-hospital3 (3.6)13 (15.4)68 (81.0)Pathologies, n (%) RA11 (9.7)16 (14.2)86 (76.1)0.20 AS2 (2.7)17 (23.3)54 (74.0) Other0 (0.0)1 (1.3)6 (85.7)Median disease duration \[IQR\]8 \[7; 18\]8 \[3; 17\]11 \[5; 19\]0.49Median time before treatment initiation \[IQR\]4 \[2; 7\]3 \[2; 6\]3 \[1; 6\]0.61Injection frequency, n (%) 1/week (Etanercept)9 (8.3)18 (16.7)81 (75.0)0.89 1/15 days (Adalimumab, Certolizumab)4 (5.9)13 (19.1)51 (75.0) 1/month (Golimumab)0 (0.0)3 (17.7)14 (82.3)BIOSECURE score, mean ± SD75.6 ± 18.077.1 ± 10.775.7 ± 13.40.91[^2]

Discussion {#S0004}
==========

We found that a majority (75.7%) of patients with CIR displayed good adherence to anti-TNF treatment after receiving TPE. This finding was consistent with the good adherence level reported by Smolen et al (70.6--74.1%), in a study of 3390 patients (RA: n=1943; AS: n=812, PsA: n=635), based on the Morisky MMAS-4© questionnaire.[@CIT0001] However, Smolen et al did not report whether those patients benefitted from TPE. We found that anti-TNF adherence did not differ between patients with different types of CIR; this finding contrasted with the findings of Smolen et al, who demonstrated identical anti-TNF adherence in patients with RA and PsA, but worse adherence in patients with AS.[@CIT0001] In our study, adherence was not impacted by the disease duration or to the number of sessions attended by the patient. However, adherence was better in older subjects than in younger subjects, consistent with Smolen et al. In addition, that study showed that anti-TNF adherence was improved among patients that believed the treatment would be effective, compared to those that worried about the inherent risks of treatment, based on the Beliefs about Medicine Questionnaire.[@CIT0021]

We tested three different education models. Of these, we found that anti-TNF adherence was worse in patients that received both individual and group TPE sessions, compared to those that received either an individual consultation only or information only. No other studies are available in the literature for comparing our findings; however, the Stockl study demonstrated the value of implementing an individual TPE program delivered by pharmacists and nurses. They found that an individual TPE program improved patient adherence to biotherapy, compared to current care practices.[@CIT0012] Similarly, individual TPE sessions were effective in improving adherence in patients with RA that underwent conventional long-term treatments. Indeed, Ravindra et al reported better adherence to conventional long-term treatments in 64 patients that had received two individual TPE sessions with doctors, compared to a control group that received typical care.[@CIT0008] Telephone-based TPE, provided by pharmacists, was also shown to have a significant impact on treatment adherence in various types of chronic disease, including RA.[@CIT0009] In contrast, Bruce and Helliwell found, in two randomized studies, that group TPE sessions did not impact adherence to long-term conventional treatments in RA[@CIT0022],[@CIT0023] compared to subjects managed with current clinical practices. In that study, the TPE comprised four to six group sessions covering patient understanding of the disease, treatments, and their beliefs.[@CIT0022],[@CIT0023]

The present study also found that anti-TNF adherence was not associated with knowledge, which was assessed with the Biosecure score. We speculated that the group TPE sessions in our study might have generated false beliefs, brought up by certain patients, which then gave rise to an inverse correlation between fear of treatment and treatment adherence in CIR (1). Regardless of whether that was true, our findings, combined with those in the literature, should encourage Rheumatology departments to improve anti-TNF adherence by offering patients individual TPE consultations, rather than group TPE sessions, when subcutaneous anti-TNF treatment is required. However, our findings require confirmation in future studies.

Conclusion {#S0005}
==========

This study demonstrated good adherence to anti-TNF treatment in patients that received TPE, particularly when it was delivered in individual sessions.
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[^1]: **Note:** \**p*-value \<0.05.

    **Abbreviations:** SD, standard deviation; RA, rheumatoid arthritis; AS, ankylosing spondyloarthritis; IQR, interquartile range.

[^2]: **Note:** *\*p*-value\<0.05.

    **Abbreviations:** SD, standard deviation; RA, rheumatoid arthritis; AS, ankylosing spondyloarthritis; IQR, interquartile range.
